Arena Pharmaceuticals (ARNA): Ralinepag positive in phase II PAH study

• Arena Pharmaceuticals (ARNA) reported its pulmonary arterial hypertension (PAH) treatment ralinepag demonstrated a significantly positive results in a phase 2 clinical trial involving 61 patients.
• It is an experimental drug to treat a rare form of lung disease.
• The biotech will now move to a Phase 3 clinical program. 

  

Arena Pharmaceuticals (ARNA) said that an experimental drug that targets a rare but deadly lung disease met its primary goal in a Phase II study.

Arena said that ralinepag, its treatment for pulmonary arterial hypertension, improved pulmonary vascular resistance (PVR) compared to a placebo in a 61-person study.